Investor Presentaiton

Strong track record Unique model Large moat Significant opportunity Compounding growth A unique way to invest in biopharma Maximizing • Exposure to transformative therapies • Revenue and profit diversification • Therapeutic area breadth Long weighted average portfolio duration Consistent and sustainable growth • Management team continuity • Shareholder alignment • Opportunity - entire R&D ecosystem is our pipeline ROYALTY PHARMA ROYALTY PHARMA ↓ Minimizing • Early-stage development risk • R&D and SG&A cost base • Therapeutic area bias • Highly competitive business development • Late-stage clinical binary risk 13 33

View entire presentation